Marksans Pharma
Marksans Pharma Limited, headquartered in India, is a prominent player in the global pharmaceutical industry, specialising in the development and manufacturing of generic and over-the-counter (OTC) products. Founded in 2001, the company has established a strong presence in key markets, including North America, Europe, and Asia, with a commitment to quality and innovation. With a diverse portfolio that includes formulations across various therapeutic areas, Marksans Pharma stands out for its robust research and development capabilities. The company is known for its unique approach to product development, ensuring compliance with international regulatory standards. Marksans has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Marksans Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Marksans Pharma's score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Marksans Pharma's reported carbon emissions
In 2024, Marksans Pharma reported total carbon emissions of approximately 23,130,250 kg CO2e, all of which fall under Scope 1 emissions. There were no reported emissions for Scope 2 or Scope 3. This represents a slight increase from 2023, when the company recorded about 22,110,220 kg CO2e in Scope 1 emissions. Marksans Pharma has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of Scope 2 and Scope 3 emissions data suggests a limited focus on indirect emissions, which are critical for a comprehensive climate strategy. The company’s emissions intensity metrics indicate that for every rupee of revenue, the emissions from Scope 1 and Scope 2 combined were approximately 0.00271 kg CO2e in 2024, compared to about 0.00337 kg CO2e in 2023. This reflects a need for enhanced climate commitments and strategies to address their overall environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 22,110,220 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Marksans Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
